Literature DB >> 27662308

Effects of a DJ-1-Binding Compound on Spatial Learning and Memory Impairment in a Mouse Model of Alzheimer's Disease.

Yoshihisa Kitamura1,2, Masatoshi Inden3, Yasuto Kimoto2, Kazuyuki Takata2, Daijiro Yanagisawa4, Masanori Hijioka1, Eishi Ashihara2, Ikuo Tooyama4, Shun Shimohama5, Hiroyoshi Ariga6.   

Abstract

Previously, DJ-1 modulator UCP0054278/comp-B was identified by virtual screening, where comp-B interacts with DJ-1 to produce antioxidant and neuroprotective responses in Parkinson's disease models. However, the effect of comp-B in an in vivo Alzheimer's disease (AD) model is yet undetermined. Thus, we examined the effect of comp-B on spatial learning, memory, and amyloid-β (Aβ) clearance in a transgenic mouse model of AD. We found that comp-B resolved the cognitive deficits, reduced insoluble Aβ42 levels, and prevented the degeneration of synaptic functions, thereby suggesting that comp-B may become a major compound for AD treatment.

Entities:  

Keywords:  Alzheimer’s disease; DJ-1; Parkinson’s disease; amyloid-β

Mesh:

Substances:

Year:  2017        PMID: 27662308     DOI: 10.3233/JAD-160574

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway.

Authors:  Leitao Wu; Hang Xu; Liang Cao; Tao Li; Ruru Li; Yang Feng; Jianzong Chen; Jing Ma
Journal:  Evid Based Complement Alternat Med       Date:  2017-09-28       Impact factor: 2.629

Review 2.  Park 7: A Novel Therapeutic Target for Macrophages in Sepsis-Induced Immunosuppression.

Authors:  Yanwei Cheng; Tony N Marion; Xue Cao; Wanting Wang; Yu Cao
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

Review 3.  DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives.

Authors:  Mariaelena Repici; Flaviano Giorgini
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

Review 4.  PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases.

Authors:  Domonkos Pap; Apor Veres-Székely; Beáta Szebeni; Ádám Vannay
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

5.  Immunomodulatory role of Parkinson's disease 7 in inflammatory bowel disease.

Authors:  Rita Lippai; Apor Veres-Székely; Erna Sziksz; Yoichiro Iwakura; Domonkos Pap; Réka Rokonay; Beáta Szebeni; Gábor Lotz; Nóra J Béres; Áron Cseh; Attila J Szabó; Ádám Vannay
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.